Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

March 3, 2014

Primary Completion Date

June 6, 2016

Study Completion Date

June 8, 2017

Conditions
Parkinson's Disease
Interventions
DRUG

Apomorphine hydrochloride

Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe

DRUG

Placebo

Sodium chloride 9 mg/ml

Trial Locations (20)

1220

Donauspital / SMZ-Ost, Abteilung für Neurologie, Sekretariat (Stock 1, Ebene 4), Vienna

Unknown

Medizinische Universität Graz / Univ. Klinik für Neurologie, Graz

Medizinische Universität Innsbruck, Innsbruck

Bispebjerg University Hospital, Movement Disorder Centre, Copenhagen

CHRU Clermont- Ferrand Gabriel-Montpied, Clermont-Ferrand

CHU de Rennes, Hôpital Pontchaillou, Rennes

CHU Toulouse, Hôpital Purpan, Centre d'Investigation Clinique, Toulouse

Neurologisches Fachkrankenhausfür Bewegungsstörungen / Parkinson, Beelitz-Heilstätten

Klinikum Bremerhaven-Reinkenheide gGmbH, Neurologische Klinik, Bremerhaven

Paracelsus Elena-Klinik Kassel, Kassel

Schön Klinik München Schwabing / Neurologie und Klinische Neurophysiologie, München

Universitair Medisch Centrum, Groningen

Atrium MC parkstad, Heerlen

Erasmus MC, Rotterdam

Hospital Clínic de Barcelona, Barcelona

Hospital Universitario Fundación Jiménez Díaz, Madrid

The Walton Centre Nhs Foundation Trust, Liverpool

Kings College Hospital NHS Foundation Trust, London

St George's Heathcare NHS Trust, London

Newcastle University, Clinical Ageing Research Unit (CARU), Newcastle

Sponsors
All Listed Sponsors
lead

Britannia Pharmaceuticals Ltd.

INDUSTRY